Cargando…

Occult hepatitis B in patients with cancer during immunotherapy with or without chemotherapy: A real-life retrospective single-center cohort study

INTRODUCTION: Few data about the safety of immune checkpoint inhibitors (ICIs) in the patients with solid tumor with Occult Hepatitis B Virus (OBI) are available. According to the Taormina Workshop on Occult HBV Infection Faculty Members we defined as potential-OBI (pOBI) the HBV DNA negativity with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lasagna, Angioletta, Albi, Giuseppe, Maserati, Renato, Zuccarini, Andrea, Quaccini, Mattia, Baldanti, Fausto, Sacchi, Paolo, Bruno, Raffaele, Pedrazzoli, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902935/ https://www.ncbi.nlm.nih.gov/pubmed/36761977 http://dx.doi.org/10.3389/fonc.2023.1044098

Ejemplares similares

Effectiveness of the available early therapies in reducing severe COVID-19 in non-hospitalized patients with solid tumors on active treatment
por: Lasagna, Angioletta, et al.
Publicado: (2022)

Case report: Successful outcome of COVID-19 in the context of autologous hematopoietic stem cell transplantation: The impact of the anti-SARS-CoV-2 vaccine and early remdesivir
por: Lasagna, Angioletta, et al.
Publicado: (2022)

Long-COVID in Patients with Cancer Previously Treated with Early Anti-SARS-CoV-2 Therapies in an Out-of-Hospital Setting: A Single-Center Experience
por: Lasagna, Angioletta, et al.
Publicado: (2023)

Lights and shadows on the role of rhG-CSF in cancer patients during the COVID-19 pandemic and future perspectives of research
por: Lasagna, Angioletta, et al.
Publicado: (2021)

COVID-19 and breast cancer: may the microbiome be the issue?
por: Lasagna, Angioletta, et al.
Publicado: (2020)

Development of hepatitis triggered by SARS-CoV-2 vaccination in patient with cancer during immunotherapy: a case report
por: Lasagna, Angioletta, et al.
Publicado: (2022)

Impact of proton pump inhibitors on the onset of gastrointestinal immune‐related adverse events during immunotherapy
por: Lasagna, Angioletta, et al.
Publicado: (2023)

Persistence of Immune Response Elicited by Three Doses of mRNA Vaccine against SARS-CoV-2 in a Cohort of Patients with Solid Tumors: A One-Year Follow-Up
por: Lasagna, Angioletta, et al.
Publicado: (2023)

Dynamic NLR and PLR in Predicting COVID-19 Severity: A Retrospective Cohort Study
por: Asperges, Erika, et al.
Publicado: (2023)

The Bio-Diversity and the Role of Gut Microbiota in Postmenopausal Women with Luminal Breast Cancer Treated with Aromatase Inhibitors: An Observational Cohort Study
por: Lasagna, Angioletta, et al.
Publicado: (2022)

Treatment beyond progression and locoregional approaches in selected patients with BRAF-mutated metastatic melanoma
por: Serra, Francesco, et al.
Publicado: (2021)

The Role of Pre-treatment Inflammatory Biomarkers in the Prediction of an Early Response to Panitumumab in Metastatic Colorectal Cancer
por: Lasagna, Angioletta, et al.
Publicado: (2022)

Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations
por: Paolucci, Stefania, et al.
Publicado: (2019)

Baseline Amino Acid Substitutions in the NS5A ISDR and PKR Binding Domain of Hepatitis C and Different Fibrosis Levels and Levels of Development of Hepatocellular Carcinoma in Patients Treated with DAAs
por: Paolucci, Stefania, et al.
Publicado: (2020)

Despite Vaccination: A Real-Life Experience of Severe and Life-Threatening COVID-19 in Vaccinated and Unvaccinated Patients
por: Colaneri, Marta, et al.
Publicado: (2022)

Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment
por: Lasagna, A., et al.
Publicado: (2022)

Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs
por: Paolucci, Stefania, et al.
Publicado: (2017)

Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di Oncologia Medica (AIOM)
por: Pedrazzoli, P., et al.
Publicado: (2023)

EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count
por: Paolucci, Stefania, et al.
Publicado: (2021)

In reply to: “A COVID-19 screening tool for oncology telephone triage”
por: Lasagna, Angioletta, et al.
Publicado: (2020)

Low risk of SARS-CoV-2 transmission by fomites in real-life conditions
por: Mondelli, Mario U, et al.
Publicado: (2021)

Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study
por: Lasagna, A., et al.
Publicado: (2022)

Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern
por: Lasagna, A., et al.
Publicado: (2022)

Assessing the Efficacy of Early Therapies against SARS-CoV-2 in Hematological Patients: A Real-Life Study from a COVID-19 Referral Centre in Northern Italy
por: Colaneri, Marta, et al.
Publicado: (2022)

Systematic analysis of human oncogenic viruses in colon cancer revealed EBV latency in lymphoid infiltrates
por: Fiorina, Loretta, et al.
Publicado: (2014)

Vaccination for herpes zoster in patients with solid tumors: a position paper on the behalf of the Associazione Italiana di Oncologia Medica (AIOM)
por: Pedrazzoli, P., et al.
Publicado: (2022)

Long-lasting responses with chemotherapy followed by T-cell therapy in recurrent or metastatic EBV-related nasopharyngeal carcinoma
por: Secondino, Simona, et al.
Publicado: (2023)

Gut Microbiota and B Cell Receptor (BCR) Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Is Biodiversity Correlated with Clinical Response or Immune-Related Adverse Event Occurrence? A Cross-Sectional Study
por: Zuccaro, Valentina, et al.
Publicado: (2023)

To fast, or not to fast before chemotherapy, that is the question
por: Caccialanza, Riccardo, et al.
Publicado: (2018)

Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up
por: Lasagna, A., et al.
Publicado: (2021)

Real-life lack of evidence of viable SARS-CoV-2 transmission via inanimate surfaces: The SURFACE study
por: Sammartino, José Camilla, et al.
Publicado: (2023)

Real-world outcomes of immunotherapy with or without chemotherapy in first-line treatment of advanced non-small cell lung cancer
por: Pelicon, Veronika, et al.
Publicado: (2023)

Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020
por: Percivalle, Elena, et al.
Publicado: (2020)

Lingual metastasis from renal cell carcinoma: a case report and literature review
por: Ganini, Carlo, et al.
Publicado: (2012)

Cellular DNA quantification in respiratory samples for the normalization of viral load: a real need?
por: Piralla, Antonio, et al.
Publicado: (2018)

Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients
por: Paolucci, Stefania, et al.
Publicado: (2012)

SARS-CoV-2 positivity in rectal swabs: implication for possible transmission
por: Novazzi, Federica, et al.
Publicado: (2020)

Application of neoadjuvant chemotherapy in occult breast cancer: Five case reports
por: Yang, Haisong, et al.
Publicado: (2017)

Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients
por: van Hoogstraten, L. M. C., et al.
Publicado: (2021)

An overview of viral oncology in Italy - report from the Pavia meeting on solid tumors
por: Perfetti, Vittorio, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_971tuegjcsc7a6b1bt66ttmsue